Aldatu Biosciences Named a Verizon Powerful Answers Award Winner for 2014

Verizon’s Multi-Million Dollar Challenge Generated Thousands of Innovative Ideas from across the Globe.

Boston, MA, 8th December 2014

Aldatu Biosciences is proud to announce it has been named a 2014 Powerful Answers Award winner in the Healthcare category. Verizon’s second consecutive multi-million dollar global challenge sought powerful ideas that may leverage Verizon’s cutting-edge technology and will help deliver groundbreaking solutions and social good in four core areas: education, healthcare, sustainability, and transportation.

Aldatu is one of three winners in the Healthcare category and one of 12 winners total (three in each category). The ideas that win the top prizes of $1 million in each category will be revealed on Jan. 27, 2015 in New York City. The remaining eight winners will receive $250,000 each, for a total of $6 million awarded by Verizon.

“We’re blown away by this year’s winners and look forward to revealing who will take home the top prize of $1 million. All 12 winners have shared impressive ideas and solutions and we look forward to seeing them succeed and working with them to leverage our technology and help make the world a better place.”John Doherty, senior vice president, Corporate Development for Verizon

In addition to the prize money, Aldatu has the opportunity to connect with a variety of network, business development and marketing experts, and partners across Verizon to explore ongoing collaborations.

Watch Aldatu’s participation in the Powerful Answers Awards Event live on January 27 via www.verizonwireless.com/news. And don’t forget to root for us via #VZPAA.

More information:
Verizon Powerful Answers Award 2014  // Introducing the Verizon Powerful Answers Award Winners for 2014

(BOSTON, MA) —Aldatu Biosciences, a biotechnology company developing gold standard molecular diagnostic assays and based real-time PCR, today announced it has been awarded a $3 Million Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). The award will fund the continued advancement of the company’s proprietary PANDAA™ technology platform and its specific application to the first universal, pan-filovirus detection and differentiation of Ebolavirus and Marburgvirus, the causative agents of Ebola Virus Disease and Marburg Virus Disease.

There is an urgent global unmet market need for a standardized, commercially available pan-species filovirus test that is accessible to resource-limited settings, especially considering the growing reach of the filovirus family as evidenced by the first-ever outbreak in Tanzania that was reported on March 21, 2023.  With a case fatality rate of 88%, Marburg is one of the deadliest of the hemorrhagic fevers. The WHO reported that the 2014-2016 Ebola epidemic in West Africa generated more than 28,000 cases and more than 11,000 deaths in Guinea, Liberia, and Sierra Leone and the CDC reported that more than $3.6 billion was spent to fight the epidemic.

Challenges associated with filovirus biology have previously limited the performance of qPCR in filovirus diagnostics. Many filovirus tests are lab-developed tests and are not available for broad commercial use.  Also, current RT-PCR LDTs are only able to detect regionally endemic clades.

ACCOUNT

OUR COMPANY

RESOURCES

Facebook-f Twitter Linkedin-in

© 2023 ALDATU BIOSCIENCES 2023